We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ligand Pharmaceuticals has earned a $1 million milestone payment from GlaxoSmithKline
with that company's commencement of Phase II trials of SB-497115, an oral,
small molecule drug that mimics the activity of thrombopoietin, a protein
factor that promotes growth and production of blood platelets.
Aethlon Medical has retained Sunil Sawhney, the former director of Boston
Scientific India, and other regulatory advisors from Qualtran LLC to manage
clinical studies to treat patients infected with HIV in India.
Alfacell, a leader and pioneer in the research, development and commercialization
of ribonucleases for the treatment of cancer and other therapeutic applications,
has initiated a multicenter, open-label, Phase I/II trial to evaluate Onconase
in patients with refractory non-small cell lung cancer.
Palatin Technologies and King Pharmaceuticals have announced positive results
of a Phase IIa pilot clinical study evaluating PT-141 in premenopausal women
diagnosed with female sexual dysfunction (FSD).
Vicuron Pharmaceuticals has announced results from its Phase III clinical trial
evaluating anidulafungin for the treatment of invasive candidiasis/candidemia,
the most common hospital-acquired fungal infection.
Lorus Therapeutics has announced that an independent data safety monitoring
board (DSMB) reported that the company's ongoing Phase III registration clinical
trial in advanced pancreatic cancer, for its lead anticancer drug Virulizin,
can continue without modification to the Phase III study design.
Bolder BioTechnology has been issued a patent for proprietary methods developed
by the company to manufacture proteins and modified proteins containing unpaired
cysteine.
Viragen and its majority-owned subsidiary, Viragen International, have
announced that an application has been filed with the Swedish regulatory authorities
seeking to expand the approval for Multiferon to include the first-line adjuvant
treatment of high-risk malignant melanoma, following dacarbazine after surgical
removal of tumors.